Related Experiment Video

Updated: Sep 14, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

13.9K

Raf-kinase inhibitor protein (RKIP): A therapeutic target in colon cancer

Seema Kumari1, Sujatha Peela1, Pallaval Veera Bramhachari2

  • 1Department of Biotechnology, Dr. B.R. Ambedkar University, Srikakulam AP-532410, India.

Biochimica Et Biophysica Acta. Reviews on Cancer
|July 18, 2025
PubMed

Insights

Raf-kinase inhibitor protein (RKIP) downregulation promotes colorectal cancer (CRC) metastasis by affecting key signaling pathways. Restoring RKIP levels offers potential therapeutic strategies for CRC treatment.

Area of Science:

  • Molecular Biology
  • Oncology
  • Cell Signaling

Background:

  • Raf-kinase inhibitor protein (RKIP) is crucial for cell homeostasis.
  • RKIP downregulation is observed in various cancers, notably colorectal cancer (CRC).
  • RKIP regulates critical signaling pathways including MAPK, NF-κB, STAT3, cell cycle, and GPCR signaling.

Purpose of the Study:

  • To review the role of RKIP in colorectal cancer (CRC) aggressiveness and metastasis.
  • To detail signaling pathways affected by RKIP expression changes in CRC.
  • To discuss potential therapeutic strategies targeting RKIP in CRC.

Main Methods:

  • Literature review focusing on RKIP's function in cell signaling and cancer.
  • Analysis of signaling pathways modulated by RKIP, including MAPK and NF-κB.
  • Examination of therapeutic strategies and clinical implications related to RKIP in CRC.

Main Results:

  • RKIP binds Raf-1, inhibiting phosphorylation and inactivating signaling molecules.
  • RKIP maintains NF-κB in an inactive state by preventing phosphorylation of associated proteins.
  • Reduced RKIP expression correlates with increased CRC metastasis and cancer progression signaling.

Conclusions:

  • RKIP plays a significant role in suppressing CRC aggressiveness and metastasis.
  • Modulating RKIP expression through targeted therapies, miRNA, immunotherapy, or combined approaches holds clinical potential for CRC.
  • Understanding RKIP's intricate role in signaling pathways is key for developing effective CRC treatments.
Keywords:
Colon cancerDrug resistanceImmune suppressionMetastasisRKIPTumor suppressor

More Related Videos

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.2K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.4K